Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality

New data from Ascend’s R&D team demonstrate up to 3-fold increase in AAV yields supporting greater efficiency and scalability across gene therapy programs. Munich, Germany — 10th November 2025 — Ascend Advanced Therapies today makes public data demonstrating the performance of two proprietary manufacturing enhancers that deliver a substantial increase in adeno-associated virus (AAV) production Read More The post Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality appeared first on Ascend .